Agios Pharm
USUSDAgios Pharm (LSE:0HB0) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- agios.com
- Relazioni con gli Investitori
- investor.agios.com/
- Settore
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Centrale
- Cambridge, United States
- Amministratore Delegato
- Brian M. Goff
- Dipendenti
- 539
- Fondata
- 2008
- Azioni in Circolazione
- 59.7 Mln al 2026-07-24
- Flottante
- 50.02 Mln
- Capitalizzazione di Mercato
- 2 Mld USD
- Insider
- 1.07%
- Investitori Istituzionali
- 112.31%
- Settore (SIC)
- Pharmaceutical Preparations
- ISIN
- US00847X1046
- LEI
- 529900ONJHY8EOGYT555
- FCF
- −365 Mln USD
- Debito
- ?
- Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
Descrizione
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| Blackrock Inc. | 10.81% | 6.46 Mln | 2026-06-30 |
| Farallon Capital Managem… | 9.91% | 5.92 Mln | 2026-06-30 |
| State Street Corporation | 5.92% | 3.53 Mln | 2026-06-30 |
| Lynx1 Capital Management… | 5.71% | 3.41 Mln | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 5.2% | 3.11 Mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.85% | 2.9 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 4.49% | 2.68 Mln | 2026-06-30 |
| Armistice Capital, LLC | 4.02% | 2.4 Mln | 2026-06-30 |
| Erste Asset Management G… | 3.61% | 2.15 Mln | 2026-06-30 |
| SPDR SERIES TRUST-State… | 3.54% | 2.11 Mln | 2026-08-31 |
| Nomura Asset Management… | 3.54% | 2.11 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.16% | 1.89 Mln | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.52% | 1.51 Mln | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 2.28% | 1.36 Mln | 2026-06-30 |
| Delaware Group Equity Fu… | 1.92% | 1.14 Mln | 2026-05-31 |
| VANGUARD INDEX FUNDS-Van… | 1.32% | 788 655 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 683 990 | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.08% | 646 318 | 2026-07-31 |
| Fidelity Rutland Square… | 0.88% | 526 121 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.86% | 511 994 | 2026-07-31 |
| FOUSE JACQUALYN A. (Dire… | ≈0.26% | 154 156 | 2026-06-18 |
| GHEUENS SARAH (Officer) | ≈0.09% | 54 645 | 2026-08-04 |
| SCADDEN DAVID T. (Direct… | ≈0.03% | 20 419 | 2026-06-18 |
| HO MAYKIN (Director) | ≈0.03% | 19 848 | 2026-06-18 |
| BALLAL RAHUL D. (Directo… | ≈0.03% | 15 230 | 2026-06-18 |
| SMITH CYNTHIA (Director) | ≈0.03% | 15 230 | 2026-06-18 |
| FOSTER-CHEEK KAYE I (Dir… | ≈0.02% | 12 484 | 2026-06-18 |
| ADAMS CATHERINE OWEN (Di… | ≈0.02% | 10 865 | 2026-06-18 |
| CAPELLO JEFFREY D (Direc… | ≈0.02% | 10 865 | 2026-06-18 |
| BACKSTROM JAY T (Directo… | ≈0% | 1 447 | 2026-07-08 |
Accedi con Google